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accessibility of the DNA (2). HMGB1 can 
also be released extracellularly upon acti-
vation, damage, apoptosis or  necrosis (3). 
It then acts as a damage-associated 
 molecular pattern (DAMP) or alarmin 
and can initiate and perpetuate inflamma-
tory responses. In several inflammatory 
 conditions, such as sepsis and  rheumatoid 
 arthritis, serum and tissue levels of 
HMGB1 are increased (4–6). In animal 
models of autoimmune and inflamma-
tory diseases, it has been shown that 
blocking HMGB1 can attenuate disease. 
For  instance, treatment with anti-HMGB1 
antibodies inhibited joint destruction in 
 arthritis models (7). In sepsis models, inhi-
bition of HMGB1 by anti-HMGB1 antibod-
ies suppressed proinflammatory cytokine 
 release and improved survival (8,9).
 In SLE patients, several studies have 
shown that serum levels of HMGB1 
are increased and levels associate with 
chronic renal failure is one of the most 
 severe complications and is associated 
with significant mortality (1).
 High mobility group box 1 (HMGB1) 
is a nonhistone nuclear protein that 
has a dual function. Inside the cell, it is 
ubiquitously expressed in the nucleus 
where it binds to DNA. HMGB1 can bend 
 promoter regions and interacts directly 
with nucleosomes, thereby altering the 
INTrODUcTION
Systemic lupus erythematosus (SLE) is 
a systemic autoimmune disease character-
ized by presence of autoantibodies against 
nuclear components, leading to circulat-
ing immune complexes that are deposited 
in organs, causing tissue damage. SLE 
can affect multiple organs, including skin, 
joints and kidneys.  Glomerulonephritis 
leading to persistent proteinuria and 
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complement C3 (GenWay Biotech) and 
 anti-dsDNA IgG (Alpha  Diagnostic Inter-
national) were measured by  enzyme-linked 
immunosorbent assay (ELISA), according 
to the manufacturers’ instructions. Serum 
blood urea nitrogen (BUN) levels were 
determined by the Quantichrom DIUR 
500 kit (BioAssay Systems).  Albuminuria 
was determined by ELISA (Bethyl Labo-
ratories) according to the manufacturer’s 
instructions. Plasma levels of the cytokines 
interleukin (IL)-4, IL-6, IL-17A, inter-
feron (IFN)-α and tumor necrosis factor 
(TNF)-α were measured with a  Multiplex 
panel ( ProcartaPlex Mouse  Simplex, 
 Affymetrix eBioscience) according to the 
 manufacturer’s instructions. Samples 
were measured by using the Luminex 
100 System, and data were analyzed with 
StarStation software, version 2.3 (Applied 
 Cytometry). Plasma levels of  anti-HMGB1 
were measured by an in-house  developed 
ELISA. In short,  Costar polystyrene 
plates were coated overnight with 
1 μg/mL recombinant HMGB1 (Sigma). 
Mouse plasma samples were added in 
duplicate at 500-fold or 7,500-fold dilu-
tions (for anti-HMGB1–treated mice). 
 Detection of antibodies was done with 
 rabbit  anti-mouse immunoglobulin  
G–horseradish peroxidase (IgG-HRP) 
(Dako). Levels of anti-HMGB1 were calcu-
lated against a standard curve of a known 
concentration of monoclonal  anti-HMGB1 
antibody (2G7, mouse IgG2b).
Plasma and urine levels of HMGB1 
were measured by Western blotting 
as described previously (10), by using 
polyclonal anti–HMGB1-biotin (Thermo 
Fisher Scientific) for detection.
Gene expression analysis 
by Quantitative reverse 
Transcriptase–polymerase chain 
reaction
Total RNA was extracted from 
20 10-μm-thick kidney cryosections 
by using the RNeasy Mini Plus Kit 
( Qiagen) according to the manufac-
turer’s  instructions. RNA yield, cDNA 
synthesis and quantitative polymerase 
chain reaction amplifications were 
 performed as described previously (25). 
light–dark cycle. Animals were  allowed 
ad libitum access to drinking water and 
standard chow. Animal experiments 
were approved by the local animal 
care and experimentation committee 
(DEC 6464A).
Neutralizing anti-hMGB1 antibody
Monoclonal anti-HMGB1 antibody 
(clone 2G7, IgG2b, a gift from Kevin 
Tracey at the Feinstein Institute for Med-
ical Research) was used for treatment in 
MRL/lpr mice. This antibody has been 
extensively characterized previously with 
respect to its HMGB1 neutralizing activity 
in in vitro and in vivo studies. The neutral-
izing activity of anti-HMGB1 monoclonal 
antibody (mAb) has been tested in cell 
culture assays, with both human and 
mouse macrophages, and in animal mod-
els of HMGB1-mediated damage, such as 
sepsis (8,19–24). Moreover, anti-HMGB1 
mAb 2G7 has been shown to neutralize 
the cytokine isoform of HMGB1 (19).
Treatment of the Mice with 
anti-hMGB1 antibody
Ten MRL/lpr mice were followed 
from wk 7 until wk 17 without any 
 intervention. Two groups of 12 MRL/lpr 
mice were injected intraperitoneally twice 
weekly, for 10 wks, with 50 μg/mouse 
monoclonal anti-HMGB1 antibody (clone 
2G7, IgG2b) or control IgG2b antibody 
(BioXCell). A control group of MRL/MPJ 
mice (n = 10) was left untreated. Before 
start of treatment, at wk 7, blood and urine 
was collected. Then, every 2 wks, plasma 
( ethylenediaminetetraacetic acid) was col-
lected from the saphenous vein. Urine was 
collected during 18 h at 7, 11 and 17 wks. 
At death, spleens and kidneys were har-
vested. One half of each kidney was fixed 
in formalin and embedded in paraffin; the 
remaining half was  snap- frozen in liquid 
N2 and stored at –80°C.
Laboratory Measurements
Automated total and differential 
white blood cell (WBC) counts were 
determined in whole blood obtained 
at death using the Sysmex XT-1800iV 
(Sysmex  Nederland BV). Plasma levels of 
disease activity (10–14). It has been 
 hypothesized that impaired  clearance 
and accumulation of apoptotic  debris 
in SLE might lead to increased HMGB1 
levels locally and systemically. Further-
more, higher levels of HMGB1 were 
 observed in serum from patients with 
renal  involvement compared with 
 patients without renal involvement 
(10,13).  Kidney biopsies from patients 
with lupus nephritis showed strong 
expression of HMGB1 at cytoplasmic 
and extracellular sites, suggesting active 
release of HMGB1 (11). Collectively, 
these studies suggest that HMGB1 
is an important factor in the patho-
genesis of SLE and that it represents 
a potential therapeutic target. The 
MRL/MpOlaHsd-Tnfrsf6lpr (MRL/lpr) 
mouse is a frequently used mouse strain 
that develops a severe spontaneous 
 autoimmune disease similar to SLE (15). 
Mice homozygous for the lymphopro-
liferation spontaneous mutation (Faslpr) 
show loss of Fas function leading to a 
defect in Fas-mediated apoptosis. On the 
MRL genetic background, this leads to 
extensive lymphoproliferation and gener-
ation of  autoreactive T cells. The ensuing 
disease is characterized by lymphade-
nopathy,  autoantibody  production, com-
plement activation and immune complex 
 glomerulonephritis that usually manifests 
 between 14 and 18 wks of age (16–18).
We hypothesized that HMGB1 rep-
resents a potential therapeutic target in 
SLE and that inhibition of HMGB1 will 
attenuate renal involvement in SLE. In 
this study, we therefore investigated 
whether treatment with a neutralizing 
monoclonal anti-HMGB1 antibody could 
beneficially affect the development of 
lupus nephritis in MRL/lpr mice.
MaTerIaLS aND MeThODS
Mice
Five-week-old female MRL/lpr mice 
were obtained from Harlan, and 5-wk-old  
female MRL/MPJ were  obtained from 
The Jackson Labo ratory. Mice were group-
housed in a temperature and  humidity–
controlled  environment with a 12-h 
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were lowest at wk 17. Overall, complement 
C3 was significantly decreased in MRL/lpr 
compared with MRL/MPJ (p < 0.01), but 
was not different between mice treated 
with anti-HMGB1 mAb and control mAb 
(p = 0.55, Figure 2B).
 Plasma levels of HMGB1 were ana-
lyzed at six time points (Figure 2C). GEE 
analysis demonstrated that HMGB1 sig-
nificantly increased over time in all three 
groups (p < 0.001). As expected, at all 
time points, MRL/lpr mice had higher 
levels of HMGB1 than MRL/MPJ mice 
(p < 0.05); however, no significant differ-
ences were observed between MRL/lpr 
mice treated with anti-HMGB1 mAb or 
control mAb (p = 0.32).
Plasma levels of anti-HMGB1 were 
measured at six time points by ELISA 
(Figure 2D). Anti-HMGB1 signifi-
cantly increased over time in MRL/lpr 
mice (p < 0.001), but not in MRL/MPJ 
mice. At wk 7,  before start of treat-
ment in MRL/lpr mice, plasma levels 
of  anti-HMGB1 were similar in all 
MRL/lpr and MRL/MPJ mice. At 
all of the time points, anti-HMGB1 
levels were substantially higher in 
MRL/lpr mice treated with anti-HMGB1 
mAb than with control mAb (p < 0.001, 
 Figure 2D). In MRL/MPJ mice, levels of 
anti-HMGB1 did not change over time, 
whereas in MRL/lpr mice treated with 
control mAb, anti-HMGB1 levels grad-
ually increased until wk 15, after which 
they stabilized.
Plasma levels of several proinflam-
matory cytokines were analyzed with a 
multiplex assay, as shown in Figure 3. 
At wk 7, the levels of IFN-α, IL-17A 
and IL-6 were similar in MRL/lpr and 
MRL/MPJ mice, whereas TNF-α was 
higher in MRL/lpr mice (p < 0.001). 
IL-6 levels (Figure 3A) increased 
over time in MRL/MPJ as well as in 
MRL/lpr mice; however, no differences 
were observed between MRL/lpr mice 
treated with  anti-HMGB1 mAb or con-
trol mAb. IL-17A levels (Figure 3B) 
decreased over time in MRL/MPJ as 
well as MRL/lpr mice; however, no 
differences were observed between 
treated groups. In MRL/lpr mice, 
parameters were transformed (square 
root or logarithmic) before being entered 
in the equation. p values <0.05 were 
 considered statistically significant.
All supplementary materials are available 
online at www.molmed.org.
reSULTS
plasma hMGB1 and anti-hMGB1 
Levels Increase over Time in 
Lupus-prone MrL/lpr Mice
We first analyzed plasma levels of 
HMGB1 by Western blotting in a sep-
arate cohort of 10 MRL/lpr mice from 
6 wks until 17 wks of age. As shown in 
Figure 1, plasma HMGB1 (Figure 1A) 
and anti-HMGB1 (Figure 1B) were 
clearly detectable in 6-week-old mice. 
Moreover, plasma HMGB1 levels 
 increased with age and disease pro-
gression. These results indicate that 
MRL/lpr mice have increasing plasma 
levels of HMGB1 over time and there-
fore represent an appropriate model to 
investigate whether intervention with 
an  anti-HMGB1 antibody has beneficial 
effects on the development of lupus 
 nephritis.
hMGB1 mab Treatment Does Not 
affect plasma parameters of Disease 
activity
Plasma levels of anti-dsDNA and 
complement C3 were analyzed at four 
time points in both MRL/lpr groups and 
MRL/MPJ mice (Figures 2A, B) by gen-
eralized estimating equations (GEE) anal-
ysis. At all time points, starting at wk 7, 
MRL/lpr mice had significantly higher 
levels of anti-dsDNA than MRL/MPJ mice 
(p < 0.001, Figure 2A). In MRL/lpr mice 
levels of anti-dsDNA increased over time 
and were highest at wk 17, whereas in 
MRL/MPJ mice the levels of anti-dsDNA 
increased until wk 13 and remained 
at a similar level at wk 17. Levels of 
 anti-dsDNA were similar in MRL/lpr mice 
treated with anti-HMGB1 mAb or control 
mAb (p = 0.09, Figure 2B). In MRL/lpr as 
well as MRL/MPJ mice, complement C3 
 levels decreased over time (p < 0.001) and 
The following Assay-On-Demand 
primers were used: glyceraldehyde 
3-phosphatedehydrogenase (GAPDH); 
monocyte chemoattractant protein-1 
(MCP-1), kidney injury molecule-1 
(KIM-1), neutrophil gelatinase-associated 
lipocalin (NGAL), IL-6 and TNF-α. The 
amount of target was normalized to an 
endogenous reference (GAPDH) and 
 expressed as relative  expression (2–ΔCT).
renal histopathology
The 2-μm paraffin kidney sections 
were routinely stained with hematoxylin 
and eosin (H&E) and periodic acid-Schiff 
(PAS). The slides were evaluated in 
a blinded manner by an expert renal 
 pathologist, and kidney pathology was 
evaluated using the lupus nephritis 
classification system, as described by 
Weening et al. (26). HMGB1 staining was 
performed as described previously (11).
 Complement C3 and IgG staining 
was performed on 5-μm frozen kidney 
sections with 1 μg/mL rabbit anti-C3 
antibody (Thermo Fisher Scientific) fol-
lowed by goat–anti-rabbit IgG-HRP. For 
IgG, rabbit anti-mouse IgG-HRP was 
used. Peroxidase activity was detected 
with 3,3′-diaminobenzidine, and sec-
tions were counterstained with Mayer 
hematoxylin. All sections were scored 
digitally after examination by using a 
Nanozoomer Digital Pathology Scan-
ner (NDP Scan U10074-01, Hamamatsu 
Photonics) and quantified [(number of 
positive cells × 0.5) + number of strong 
positive cells/total cells] with software of 
Aperio ImageScope (V11.2.0.780 Aperio 
Technologies).
Statistics
Data were analyzed by using SPSS 
(version 22, IBM). Data are expressed 
as median and range and were ana-
lyzed by using Mann-Whitney U test or 
 Kruskal-Wallis test. For noncontinuous 
variables, a Fisher exact test was used. 
Generalized estimating equations were 
used to analyze changes over time within 
mice, and the exchangeable  matrix 
correlation structure was used. When 
residuals were not normally  distributed, 
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all three groups of mice had increas-
ing body weight from wk 7 until death 
at wk 17, and no differences between the 
groups were observed. As expected, aver-
age spleen weight at death was increased 
in MRL/lpr mice compared with MRL/
MPJ mice (p < 0.0001); however, aver-
age spleen weight was similar between 
MRL/lpr mice treated with  anti-HMGB1 
mAb or control mAb (Supplementary 
Figure S1B). Total WBC count and dif-
ferential WBC counts were also similar 
between anti-HMGB1 and control mAb-
treated MRL/lpr mice (Supplementary 
Table S1). These results demonstrate that 
treatment with  monoclonal anti-HMGB1 
antibody does not  influence body and 
spleen weight or WBC composition.
hMGB1 mab Treatment Does 
Not affect Kidney pathology and 
proteinuria
Kidney pathology was evaluated 
by using the lupus nephritis clas-
sification system, as described by 
Weening et al. (26). MRL/MPJ mice, 
as expected, did not show any lupus 
nephritis, whereas both groups of 
MRL/lpr did (Figure 4A). Lupus ne-
phritis of MRL/lpr mice treated with 
 anti-HMGB1 mAb was classified as 
class III (n = 3) and class IV (n = 9), 
whereas mice treated with control mAb 
were classified as class II (n = 4), class III 
(n = 2) and class IV (n = 5). In all mice, 
mostly proliferative lesions were found, 
and all displayed mononuclear cell infil-
tration. In both groups, two mice showed 
vasculitis. In addition, chronicity was low, 
and two mice in both groups showed 
sclerosing lupus nephritis. None of the 
mice developed tubulointerstitial disease, 
or glomerular and/or fibrous crescents.
 Renal deposits of IgG and com-
plement C3 were determined by 
 immunohistochemistry (Figures 4A, B). 
As expected, extensive glomerular 
IgG and C3 deposits were detected in 
MRL/lpr mice when compared with 
the control MRL/MPJ mice. However, 
the extent of glomerular IgG and 
C3  deposits was  similar in MRL/lpr 
mice treated with  anti-HMGB1 mAb 
was  observed on plasma levels of 
HMGB1,  anti-dsDNA, complement C3 
and proinflammatory cytokines.
hMGB1 mab Treatment Does Not 
affect Body and Spleen Weight and 
Distribution of WBcs
To investigate whether treatment 
with anti-HMGB1 had an effect on body 
weight, mice were weighed every week. 
As shown in Supplementary Figure S1A, 
but not in MRL/MPJ mice, IFN-α 
(Figure 3C) and TNF-α ( Figure 3D) 
levels  increased significantly (p < 0.01) 
over time; however, no differences 
were observed between MRL/lpr 
mice treated with anti-HMGB1 mAb 
or mice treated with control mAb. To 
summarize, although MRL/lpr mice 
treated with anti-HMGB-1 mAb dis-
played massively increased circulating 
anti–HMGB-1  antibody levels, no  effect 
Figure 1. Plasma HMGB1 and anti-HMGB1 antibody levels increase with age in MRL/lpr 
mice. (A) Plasma HMGB1 levels were measured by Western blot at wks 6, 7, 9, 11, 13, 15 and 
17 in MRL/lpr mice (n = 11). HMGB1 levels are presented as values of fluorescence  intensity 
and were normalized against a standard of Jurkat cell lysate. (B) Plasma  anti-HMGB levels 
(ng/mL) were measured by ELISA at wks 6, 7, 9, 11, 13, 15 and 17 in MRL/lpr mice (n = 11). 
Anti-HMGB1 levels are presented as values of fluorescence intensity and were normalized 
against a standard of monoclonal anti-HMGB1 antibody.
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hMGB1 mab Treatment Does Not 
affect proinflammatory cytokine and 
Injury-related Gene expression in the 
Kidney
To further investigate renal inflamma-
tion, mRNA levels of the proinflamma-
tory cytokines IL-6, TNF-α and MCP-1 
and of renal injury–related biomarkers 
NGAL and KIM-1 were assessed in 
kidneys (Figure 6). As expected,  levels 
of IL-6, TNF-α, NGAL and MCP-1 
were higher in MRL/lpr mice com-
pared with MRL/MPJ mice (p < 0.05). 
However, KIM-1 levels (Figure 6E) 
were  comparable between MRL/MPJ 
and MRL/lpr mice, confirming renal 
histology in which no tubulointerstitial 
disease was observed. No differences 
were found in expression levels of all 
investigated genes between MRL/lpr 
mice treated with anti-HMGB1 mAb 
or control mAb (Figure 6), confirming 
the results of renal histology that treat-
ment with anti-HMGB1 mAb does not 
 influence kidney damage.
DIScUSSION
Lupus nephritis is one of the most 
severe complications of SLE and is 
 associated with significant mortality. 
In SLE, HMGB1 serum levels are asso-
ciated with disease activity and renal 
involvement; therefore, it was proposed 
that HMGB1 might represent a potential 
therapeutic target in SLE (11,12,27). By 
using the lupus-prone MRL/lpr mouse 
model, we show that administration of 
neutralizing monoclonal anti-HMGB1 
antibodies does not affect development 
of lupus nephritis, disease progression or 
 proinflammatory cytokine expression.
In accordance with observations 
in  patients with SLE (10–14), plasma 
HMGB1 levels were increased in 
 lupus-prone MRL/lpr mice compared 
with the control MRL/MPJ mice that do 
not develop disease. Moreover, HMGB1 
levels  increased with disease progres-
sion, which again is in agreement with 
observations in SLE patients where 
serum HMGB1 levels correlate with 
the SLE disease activity index (10,14). 
Upon development of lupus nephritis 
Renal injury was also evaluated 
by 18-h albumin excretion into the 
urine (Figure 5B). At wks 7 and 
11, urinary albumin excretion was 
similar in MRL/lpr and MRL/MPJ 
mice. At wk 17, urinary albumin ex-
cretion was highly increased in the 
MRL/lpr mice but not in MRL/MPJ 
mice (p < 0.0001). However, albumin-
uria was similar in MRL/lpr mice 
treated with anti-HMGB1 mAb or 
control mAb. Urine HMGB1 levels 
were  analyzed by Western blotting 
(Figure 5C). At wks 7 and 11, urine 
HMGB1 was undetectable in all mice. 
At wk 17, urine HMGB1 levels were 
increased in MRL/lpr mice; however, 
no difference between treated groups 
was seen. To summarize, MRL/lpr mice 
displayed renal injury characteristic of 
lupus  nephritis, which was unaffected 
by treatment with  anti-HMGB1 mAb.
or  control mAb. As expected, HMGB1 
staining showed nuclear staining 
in kidneys from MRL/MPJ mice 
( Supplementary Figure S2). In  kidneys 
from MRL/lpr mice,  extracellular 
HMGB1 was  observed.  Moreover, 
there were also HMGB1- negative 
nuclei (blue staining) present, which 
suggests  active release of HMGB1 from 
these cells, but there was no difference 
 between mice treated with  anti-HMGB1 
mAb or control mAb.
 Renal function was determined by 
measuring BUN levels at wks 7, 11 and 
17 (Figure 5A). At wk 7, BUN levels 
were similar in MRL/lpr and MRL/MPJ 
mice, while at wks 11 and 17, BUN levels 
were increased in both groups (MRL/lpr 
mice compared with MRL/MPJ mice) 
(p < 0.01). There were no differences in 
BUN levels between mice treated with 
anti-HMGB1 mAb or control mAb.
Figure 2. Anti-HMGB1 mAb treatment of MRL/lpr mice does not affect plasma levels of 
HMGB1, anti-dsDNA antibodies and complement C3, while increasing HMGB1 antibody 
levels. (A) Plasma anti-dsDNA (units/mL) was measured by ELISA in MRL/MPJ (n = 10) and 
MRL/lpr (n = 10–12) mice at wks 7, 9, 13 and 17. (B) Plasma complement C3 (mg/mL) 
was measured by ELISA in MRL/MPJ (n = 10) and MRL/lpr (n = 10–12) mice at wk 7, 9, 13 
and 17. (C) Plasma HMGB1 was measured by Western blotting in MRL/MPJ (n = 10) and 
MRL/lpr (n = 10–12) mice at wks 7, 9, 11, 13, 15 and 17. HMGB1 levels are presented as val-
ues of fluorescence intensity and were normalized against a standard of Jurkat cell lysate. 
(D) Plasma anti-HMGB1 (ng/mL) was measured by ELISA in MRL/MPJ (n = 10) and MRL/lpr 
(n = 10–12) mice at wks 7, 9, 11, 13, 15 and 17. Anti-HMGB1 levels are presented as 
 values of fluorescence intensity and were normalized against a standard of monoclonal 
 anti-HMGB1 antibody. Depicted are the median values with range at each time point.
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portal vein of the liver together with the 
transplanted islets (28).  Collectively, 
these studies demonstrate that the 
 anti-HMGB1 mAb 2G7, in comparable 
dosages and using similar administration 
routes, confers protective effects in vari-
ous inflammatory disease models.
In addition, a number of studies, albeit 
using different anti-HMGB1  antibodies 
that also recognize a different epitope, 
have shown beneficial effects of treatment 
with anti-HMGB1 antibodies in mouse 
models of sepsis and renal  ischemia/
reperfusion (8,30). In these models, it was 
demonstrated that HMGB1 is an early 
 mediator of damage and that neutral-
ization of HMGB1 inhibits downstream 
effects, such as release of proinflammatory 
cytokines. However, these models rep-
resent  reversible acute disease  models, 
2G7 has been successfully used in vari-
ous models of inflammation in which a 
proinflammatory effect of HMGB1 was 
suspected. For example, intraperitoneal 
administration of mAb 2G7 in a mouse 
model of rheumatoid arthritis amelio-
rated development of arthritis. In this 
specific study, either 100 μg/mouse was 
injected every second day for 5 wks or 
70 μg/mouse daily for 1 wk (7,28). More-
over, intraperitoneal administration of a 
single dose of mAb 2G7 (10 μg/mouse) 
24 h after cecal ligation and puncture sig-
nificantly improved survival in this sep-
sis model (29). In addition, mAb 2G7 has 
been shown to prevent TLR4- mediated 
early graft failure after pancreatic 
islet graft transplantation; however, 
in this specific study, the antibody 
(50 μg/mouse) was injected into the 
at wk 17, HMGB1 was also detectable in 
urine, as was also shown in patients (11). 
In line with renal HMGB1 immunohis-
tochemistry in patients, we observed 
HMGB1 expression at extracellular sites 
in kidneys from MRL/lpr mice, which 
suggests active release of HMGB1. 
Collectively, these data indicate that 
HMGB1 release occurs in the MRL/lpr 
mouse model and that, also with respect 
to HMGB1, this mouse model reflects 
human disease.
However, as we describe here, 
 intraperitoneal administration of the 
monoclonal anti-HMGB1 antibody 
2G7 to lupus-prone MRL/lpr mice 
(50 μg/mouse twice weekly from wk 7 
until wk 17) did not ameliorate devel-
opment of lupus nephritis. Previously, 
the  monoclonal anti-HMGB1 antibody 
Figure 3. Anti-HMGB1 mAb treatment of MRL/lpr mice does not affect plasma levels of proinflammatory cytokines. Plasma levels of the 
cytokines IL-6 (A), IL-17A (B), IFN-α (C) and TNF-α (D) were measured by multiplex in MRL/MPJ and MRL/lpr mice at wks 7, 9, 13 and 17. 
Box and whiskers plot, median and interquartile range are shown for n = 6–8 mice per group. Separate dots indicate outliers.
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of arthritis (31,32) and sepsis (8), 
 administration of Box A exerted beneficial 
effects on disease progression. It should 
be noted, however, that RAGE is only one 
of the receptors for HMGB1, and hence it 
is likely that not all effects of HMGB1 will 
be inhibited when using Box A.
In addition, Li et al. recently  reported 
that blocking serum HMGB1 with 
 glycyrrhizin, a traditional herbal medi-
cine that blocks HMGB1, alleviated lupus 
nephritis induced in mice by activated 
 lymphocyte-derived DNA (ALD-DNA) 
(33). In this model, lupus  nephritis is 
 induced by active immunization of 
mice with DNA from lymphocytes that 
have undergone  activation-induced cell 
death (ALD-DNA) in complete Freund’s 
 adjuvant. After  induction, serum HMGB1 
levels  gradually increased. Glycyrrhizin 
treatment attenuated HMGB1 as well as 
circulating proinflammatory cytokine levels 
and alleviated renal  pathology. However, 
for glycyrrhizin, a range of  biological effects 
were reported, including antiinflamma-
tory, antioxidant, free  radical-scavenging, 
antiulcer, antihepatotoxic, antimicrobial, 
cytoprotective and cytotoxic activities 
(34,35). Therefore, it is unclear whether 
 glycyrrhizin exerts its beneficial effects 
solely via blocking of HMGB1 in this  
ALD-DNA–induced lupus mouse model.
The results presented here  appear 
to contradict a recent study by 
Zhang et al. (36) showing that treatment 
with anti-HMGB1 antibodies  reduced 
 lupus-like disease, including proteinuria 
and glomerulonephritis, in  lupus-prone 
BXSB mice (36). Lupus in BXSB mice is 
characterized by lymph node and spleen 
enlargement,  hypergammaglobulinemia, 
anti- nuclear antibodies and immune com-
plex glomerulonephritis, which usually 
becomes evident at around 5 months 
of age. A duplicated copy of the TLR7 
gene is primarily responsible for the 
autoimmune  phenotype. In MRL/lpr, 
we demonstrated that plasma HMGB1 
levels are elevated upon disease devel-
opment, but it is unclear whether the 
same holds true for the BXSB lupus 
mouse model. Moreover, the source of the 
 anti-HMGB1 antibody used in the study 
 neutralization of HMGB1 does not halt or 
improve lupus nephritis development.
Inhibition of HMGB1 activity can 
be achieved in different ways. In our 
study, we used anti-HMGB1 antibodies 
to  neutralize HMGB1. An alternative 
 approach is to use the competitive 
 receptor antagonist Box A to prevent 
binding of HMGB1 to its receptor 
 receptor for  advanced glycation end 
products (RAGE). In mouse  models 
whereas our lupus nephritis model 
 represents a chronic irreversible disease. 
In acute diseases, HMGB1 may act as an 
early alarmin that can initiate downstream 
proinflammatory signaling. In SLE, dis-
ease development occurs gradually and is 
 multifactorial; hence, HMGB1 represents 
only one of the many proinflammatory 
factors that can activate the immune 
 system and cause damage. This  contention 
is supported by our finding that 
Figure 4. Anti-HMGB1 mAb treatment of MRL/lpr mice does not affect renal pathology 
and renal immune complex deposition. (A) Representative pictures of PAS, H&E, C3 and 
IgG staining in kidney sections of 17-wk-old MRL/MPJ and MRL/lpr mice (10×). Inserts 
show a glomerulus in detail (40×). (B) Quantitative analysis of C3 and IgG deposition in 
kidney sections of 17-wk-old MRL/MPJ and MRL/lpr mice. Box and whiskers plot, median 
and  interquartile range are shown for n = 8–11 mice per group. A Kruskal-Wallis test 
was used to test for overall differences between the three groups. To investigate which 
group was different, further testing was performed to compare groups separately using a 
Mann-Whitney U test. *p < 0.05
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antibody and treatment regimen. These in-
conclusive or contradictive results warrant 
further studies in different mouse models 
of SLE such as mice that lack MFGE8.
from wk 16 until wk 26. Therefore, the dif-
ferences between our study and the data 
from Zhang et al. might be explained by 
differences in mouse model, anti-HMGB1 
by Zhang et al. is different from ours, and 
a different treatment regimen was used 
that consisted of 10 μg/mouse injected 
intraperitoneally three times a week 
Figure 5. HMGB1 mAb treatment of MRL/lpr mice does not affect albuminuria and HMGB1 urine levels. (A) Renal function was determined 
by measuring BUN levels at wks 7, 11 and 17. (B) Albumin was measured by ELISA in 18-h urine of MRL/MPJ (n = 10) and MRL/lpr (n = 10–12) 
mice at wks 7, 11 and 17. (C) HMGB1 was measured by Western blotting in 18-h urine of MRL/MPJ (n = 10) and MRL/lpr (n = 10–12) mice 
at wks 7, 11 and 17. HMGB1 levels are presented as values of fluorescence intensity and were normalized against a standard of Jurkat cell 
lysate. A Kruskal-Wallis test was used to test for overall differences between the three groups at each time point. To investigate which group 
was different, further testing was performed to compare groups separately using a Mann-Whitney U test. Box and whiskers plot, median and 
interquartile range are shown for n = 8–12 mice per group. Separate dots indicate outliers. ***p < 0.0001. ns, Nonsignificant.
Figure 6. Anti-HMGB1mAb treatment of MRL/lpr mice does not affect renal mRNA levels of IL-6, TNF, MCP-1, NGAL or KIM-1. Expression 
levels of TNF-α (A), IL-6 (B), MCP-1 (C), NGAL (D) and KIM-1 (E) mRNA were analyzed in kidney tissues of MRL/MPJ mice (n = 8) and 
MRL/lpr mice treated with control (n = 11) and mice treated with monoclonal anti-HMGB1 (n = 9). Data are shown as relative expression 
compared with GAPDH. Box and whiskers plot, median and interquartile range are shown. Separate dots indicate outliers. A Krus-
kal-Wallis test was used to test for overall differences between the three groups. To investigate which group was different, further testing 
was performed to compare groups separately using a Mann-Whitney U test. *p < 0.05; **p < 0.01. ns, Nonsignificant.
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that might be perceived to influence the 
results and discussion reported in this 
paper.
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the  anti-HMGB1 mAb. However, earlier 
studies using this antibody in animal 
models of rheumatoid arthritis did not 
observe a  reduced effect of anti-HMGB1 
mAb (7).
Because HMGB1 is known to induce 
proinflammatory cytokine release 
from immune cells, we also measured 
plasma proinflammatory cytokine  levels. 
In vitro, HMGB1 has been shown to 
induce TNF-α release from mouse mac-
rophages (40,41) and IFN-α production 
from dendritic cells (42). In MRL/lpr 
mice, we observed increasing plasma 
levels of TNF-α and IFN-α over time. 
However, it is unclear whether these 
proinflammatory cytokines are induced 
solely by HMGB1 and/or are derived 
from autoreactive lymphocytes that are 
continuously present in MRL/lpr mice. 
Regardless of the source, we observed 
no effect of anti-HMGB1 antibody 
treatment on plasma proinflammatory 
 cytokine levels.
Taken together, our data show that, 
although HMGB1 levels are increased in 
MRL/lpr mice, treatment with a mono-
clonal anti-HMGB1 antibody does not 
inhibit development or affect progression 
of lupus nephritis. Further studies are 
needed to validate these results in other 
mouse models of SLE.
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Plasma HMGB1 levels, measured by 
Western blotting, were unaffected in 
MRL/lpr mice treated with neutralizing 
monoclonal anti-HMGB1 antibodies. 
We used Western blotting to detect 
HMGB1, since we and others have 
previously shown that serum proteins 
and antibodies interfere in the HMGB1 
ELISA (10,37). However, because of 
denaturation and high temperatures in 
Western blotting, immune complexes are 
dissociated, and the HMGB1 measured 
probably consists of free HMGB1 and 
previously  complexed HMGB1. Our 
findings seem to imply that complexes 
of HMGB1–anti-HMGB1 that are formed 
during treatment are not cleared from the 
circulation, which can be explained by 
the fact that the antibody used is a neu-
tralizing but not a depleting antibody.
MRL/lpr mice develop lymphade-
nopathy leading to the presence of 
autoreactive lymphocytes. Activated 
lymphocytes are a source of extracellu-
lar HMGB1 (38), which can contribute 
to high levels of HMGB1 in the spleen 
or lymph nodes. Therefore, because 
of high levels of HMGB1 locally, the 
dose of mAb 2G7 used here may have 
been insufficient to neutralize HMGB1 
completely. Although we cannot ex-
clude this possibility, previous studies 
in BXSB lupus mice and a sepsis model 
have clearly shown a positive effect of 
anti-HMGB1 antibody treatment, de-
spite the development of splenomegaly 
(21,36).
In untreated MRL/lpr mice, plasma 
levels of HMGB1 and anti-HMGB1 in-
crease over time with disease progres-
sion, which is in line with data from SLE 
patients (10,39). In the disease models 
described by Li et al. and Zhang et al., 
which do show a positive effect of block-
ing HMGB1, it is unclear whether 
anti-HMGB1 antibodies are also present 
(33,36). At present, the role of endoge-
nously formed anti-HMGB1 antibodies 
in disease pathogenesis is unclear and 
warrants further investigation. It is also 
possible that rheumatoid factors, which 
can be present in serum from MRL/lpr 
mice, can interfere with the activity of 
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